Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.72 USD | -0.21% | +2.67% | -16.41% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 194.22 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.71 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.41% | 84.36B | B- | ||
+32.09% | 693B | C+ | ||
+29.39% | 584B | B | ||
-1.34% | 372B | C+ | ||
+20.34% | 332B | B- | ||
+7.39% | 294B | C+ | ||
+14.25% | 239B | B+ | ||
-3.03% | 211B | A+ | ||
+10.02% | 210B | B- | ||
+8.49% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GILD Stock
- Ratings Gilead Sciences, Inc.